Vident Investment Advisory, LLC Mirati Therapeutics, Inc. Transaction History

Vident Investment Advisory, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 12, 2019	SELL	$59.49 - $104.71 $2.22 Million - $3.91 Million	-37,304 Closed	0 $0
Q1 2019 May 08, 2019	SELL	$43.65 - $78.95 $56,875 - $102,871	-1,303 Reduced 3.38%	37,304 $2.73 Million
Q4 2018 Feb 14, 2019	SELL	$32.0 - $47.43 $287,168 - $425,636	-8,974 Reduced 18.86%	38,607 $1.64 Million
Q3 2018 Nov 14, 2018	SELL	$47.1 - $62.7 $161,600 - $215,123	-3,431 Reduced 6.73%	47,581 $2.24 Million
Q2 2018 Aug 14, 2018	BUY	$26.05 - $52.4 $1.33 Million - $2.67 Million	51,012 New	51,012 $2.52 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.